Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV +0.12%41 Days Inventory is 227.05 as of Dec. 2025, which is 68% above its 10-year median of 135.05. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Bio View ranks worse than 71.19% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Bio View's Average Total Inventories for the
six
months ended in Dec. 2025 was ₪6.65 Mil. Bio View's Cost of Goods Sold for the
six
months ended in Dec. 2025 was ₪5.35 Mil.
Hence, Bio View's Days Inventory for the
six
months ended in Dec. 2025 was 227.05.
The historical rank and industry rank for Bio View's Days Inventory or its related term are showing as below:
XTAE:BIOV'
s Days Inventory Range Over the Past 10 Years
Min: 92.71 Med: 135.05 Max: 264.93
Current: 253.03
During the past 13 years, Bio View's highest Days Inventory was 264.93. The lowest was 92.71. And the median was 135.05.
XTAE:BIOV's Days Inventory is ranked worse than 71.19% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 177.785
vs XTAE:BIOV: 253.03
Bio View's Days Inventory
declined
from Dec. 2024 (337.33) to Dec. 2025 (227.05).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bio View's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.80.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bio View's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.62.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Bio View's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bio View's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Bio View Days Inventory Related Terms
Bio View Days Inventory Historical Data
* Premium members only.
The historical data trend for Bio View's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BIOV vs ABT, SYK, MDT: Days Inventory Comparison
For the Medical Devices subindustry, Bio View's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Days Inventory distribution charts can be found below:
* The bar in red indicates where Bio View's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a Days Inventory of 227.05 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bio View and its competitors. This is 68% above median its historical median of 135.05. Over the past decade, Bio View's Days Inventory has ranged from 92.71 to 264.93. According to the industry distribution chart, Bio View ranks #561 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 71.2%.
Is Bio View's Days Inventory too high?
Bio View's current Days Inventory of 227.05 is 68% above median its 10-year median of 135.05. Over the past 10 years, this metric has ranged from a low of 92.71 to a high of 264.93. The Medical Devices & Instruments industry median Days Inventory is 177.79. Bio View's value of 227.05 is 27.7% above this industry median. Based on the distribution chart, Bio View ranks #561 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's Days Inventory compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #561 out of 788 companies for Days Inventory. This places Bio View in the lower half of its industry. The industry median Days Inventory is 177.79. Bio View's value of 227.05 is 27.7% above this benchmark. Historically, Bio View's own Days Inventory has ranged from 92.71 to 264.93 over the past decade. While the company's 10-year median is 135.05 vs. the industry median of 177.79, Bio View has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 177.79, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio View's current Days Inventory of 227.05 is 27.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bio View and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 177.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio View's current Days Inventory is 227.05, which is 68% above median its own 10-year median of 135.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current Days Inventory is 227.05, which is 68% above median its 10-year median of 135.05 and 27.7% above the Medical Devices & Instruments industry median of 177.79. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current Days Inventory is 227.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
Days Inventory: 227.05 (68% above median its 10-year median of 135.05)
GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
Industry Position: 27.7% above the Medical Devices & Instruments median (#561 of 788)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
